SPRUCE BIOSCIENCES, INC.

For the period ended Sep 30, 2026. Filed Nov 9, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 9, 2026

SPRB$46.67-5.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Additional · Total
Common Stock · Paid-In · Accumulated · Stockholders'
	Shares	Amount	Capital	Deficit	Equity
Balance as of July 1, 2026	2,752,810	$—	$401,459	$(317,729)	$83,730
Issuance of common stock under the August 2026 Private Placement, net of offering costs of $31	121,203	—	5,469	—	5,469
Stock-based compensation	—	—	1,102	—	1,102
Net loss	—	—	—	(24,006)	(24,006)
Balance as of September 30, 2026	2,874,013	$—	$408,030	$(341,735)	$66,295

Additional · Total
Common Stock · Paid-In · Accumulated · Stockholders'
	Shares	Amount	Capital	Deficit	Equity
Balance as of January 1, 2026	1,372,043	$—	$331,750	$(289,234)	$42,516
Issuance of common stock under the August 2026 Private Placement, net of offering costs of $31	121,203	—	5,469	—	5,469
Issuance of common stock and warrants under the April 2026 Public Offering, net of offering costs of $4,562	1,380,000	—	64,438	—	64,438
Issuance of common stock related to employee stock purchase plan	532	—	2	—	2
Issuance of common stock related to vesting of restricted stock units, net of tax withholdings	235	—	(10)	—	(10)
Reclassification of embedded conversion option	—	—	3,719	—	3,719
Stock-based compensation	—	—	2,662	—	2,662
Net loss	—	—	—	(52,501)	(52,501)
Balance as of September 30, 2026	2,874,013	$—	$408,030	$(341,735)	$66,295

Additional · Total
Common Stock · Paid-In · Accumulated · Stockholders'
	Shares	Amount	Capital	Deficit	Equity
Balance as of July 1, 2025	563,042	$—	$279,556	$(266,376)	$13,180
Issuance of common stock related to employee stock purchase plan	449	—	3	—	3
Stock-based compensation	—	—	415	—	415
Net loss	—	—	—	(8,212)	(8,212)
Balance as of September 30, 2025	563,491	$—	$279,974	$(274,588)	$5,386

Additional · Total
Common Stock · Paid-In · Accumulated · Stockholders'
	Shares	Amount	Capital	Deficit	Equity
Balance as of January 1, 2025	563,042	$—	$279,089	$(250,268)	$28,821
Issuance of common stock related to employee stock purchase plan	449	—	3	—	3
Stock-based compensation	—	—	882	—	882
Net loss	—	—	—	(24,320)	(24,320)
Balance as of September 30, 2025	563,491	$—	$279,974	$(274,588)	$5,386

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.